ApoImmune, Inc. | 1044 East Chestnut Street | Louisville, KY 40204 | 502-212-2493 | info@apoimmune.com { ProtEx, ApoVax, ApoVax104, Steven T. Downey, Haval Shirwan Ph.D., George Emont, Steve Gailar }

Press Room

Latest News


12/3/09	ApoImmune Named a Top Innovator Winner
5/1/09	ApoImmune Finalist for "Best Early-Stage Vaccine Biotech" at World Vaccine Congress ViE Awards
12/9/08	ApoImmune Named 2008 Hot Dozen Company
11/1/08	Kentucky SBIR-STTR Matching Funds Program Awards ApoImmune $100,000 for NIH Phase I SBIR Tuberculosis Vaccine Grant
10/15/08	ApoImmune Chosen for Participation in National Institutes of Health SBIR Commercialization Assistance Program (CAP)
10/1/08	ApoImmune Awarded $500,000 from Kentucky SBIR-STTR Matching Funds Program
8/31/08	NIH Awards ApoImmune Phase I Grant for Tuberculosis Vaccine Development
7/31/08	ApoImmune Awarded Phase II SBIR Grant for Continued Development of Novel Cervical Cancer Vaccine
10/1/07	Kentucky SBIR-STTR Matching Funds Program Awards ApoImmune $100,000
9/5/07	ApoImmune, Inc. Awarded NIH Grant for Universal Cancer Vaccine
8/1/07	ApoImmune, Inc. Awarded NIH Phase I SBIR Grant for Treatment of Type 1 Diabetes
7/31/07	ApoImmune, Inc. Awarded NIH Phase I SBIR Grant for Cervical Cancer Vaccine
2/1/07	ApoImmune Awarded $100,000 from Kentucky SBIR-STTR Matching Funds Program
9/1/05	ApoImmune, Inc. Awarded NCI Phase I SBIR Grant for Vaccine Development